Clinical trials in Pozzuoli – page 34

1 231 clinical trials in Pozzuoli, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Pozzuoli at a glance

1 231

clinical trials

Research sites1

Quick filters

1 231 trials in Pozzuoli

Open in trial search

Hepatocellular carcinoma

Recruiting

Study on the Effectiveness of Durvalumab and Bevacizumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug

Study on the Effectiveness of Durvalumab and Bevacizumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Neoplasm malignant+7

Recruiting

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Exelixis Inc.

Contact Research Centre

Hormone-dependent prostate cancer

Recruiting

Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo

Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Unicancer

Contact Research Centre

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Axitinib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Juvenile idiopathic arthritis

Recruiting

Study on the Safety and Effectiveness of Baricitinib for Children Aged 1 to 17 with Juvenile Idiopathic Arthritis

Registered drugNo placebo

Study on the Safety and Effectiveness of Baricitinib for Children Aged 1 to 17 with Juvenile Idiopathic Arthritis

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Baricitinib
Sponsor:Eli Lilly & Co.

Contact Research Centre

Neoplasm

Recruiting

Study on the Safety and Tolerability of D3S-001 Alone or with Drug Combination in Adults with Advanced Solid Tumors with KRAS p.G12C Mutation

Registered drugNo placebo

Study on the Safety and Tolerability of D3S-001 Alone or with Drug Combination in Adults with Advanced Solid Tumors with KRAS p.G12C Mutation

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:D3 Bio (Wuxi) Co. Ltd.

Contact Research Centre

Non-Hodgkin's lymphoma

Recruiting

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Cyclophosphamide
Sponsor:Universitaetsklinikum Muenster AöR

Contact Research Centre

Factor VIII deficiency

Recruiting

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Efanesoctocog Alfa
Sponsor:Swedish Orphan Biovitrum AB (publ)

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

Registered drugNo placebo

Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Panitumumab
Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Contact Research Centre

Endometrial cancer+4

Recruiting

Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

InvestigationalNo placebo

Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:PC14586
Sponsor:Pmv Pharmaceuticals Inc.

Contact Research Centre

T-cell lymphoma

Recruiting

Study on the Safety and Effectiveness of LIS1 for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

InvestigationalNo placebo

Study on the Safety and Effectiveness of LIS1 for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Sponsor:Xenothera

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tocilizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Pozzuoli

What the registry says about research in the country

01 Neoplasms

Clinical trial activity in Località la Schiana, Pozzuoli is strongly focused on cancer research, with studies examining how to improve treatment options for several advanced solid tumors. The main goal is to test new therapeutic strategies and refine existing combinations for better disease control and patient outcomes.

Colorectal cancer, including metastatic and unresectable forms
Metastatic castration-resistant prostate cancer
Metastatic renal cell carcinoma
Breast cancer with hormone receptor-positive, HER2-negative disease

These studies are exploring more effective ways to slow progression, overcome treatment resistance, and improve survival in patients with advanced neoplasms.

02 Digestive System Diseases

Several trials in this site concentrate on digestive system cancers, especially advanced colorectal cancer. Research is centered on evaluating treatment effectiveness and finding better options for patients whose disease has already progressed or carries specific genetic changes.

RAS-mutant metastatic colorectal cancer
RAS/BRAF wild-type metastatic colorectal cancer
Unresectable left-sided metastatic colorectal cancer
Patients with metastatic colorectal cancer

Across these studies, the focus is on improving tumor response, extending disease control, and identifying which patients may benefit most from targeted treatment approaches.

03 Analytical, Diagnostic and Therapeutic Techniques and Equipment

This research landscape also includes therapeutic techniques aimed at improving how treatments are delivered and how response is monitored. The trials are not only testing active therapies, but also looking for better ways to understand resistance, safety, and treatment benefit in real-world patients.

Biomarker research for resistance and treatment monitoring
Safety and tolerability comparisons between treatment strategies
Quality of life assessments during therapy
Therapy optimization in advanced cancer care

In this part of the research portfolio, investigators in Pozzuoli are helping shape more precise and patient-centered cancer care.

Back to Italy All countries